EFG Asset Management Americas Corp. Raises Holdings in Natera, Inc. (NASDAQ:NTRA)

EFG Asset Management Americas Corp. increased its position in Natera, Inc. (NASDAQ:NTRA) by 277.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,311 shares of the medical research company’s stock after buying an additional 9,784 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Natera were worth $1,441,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC raised its position in Natera by 6,007.5% in the fourth quarter. International Assets Investment Management LLC now owns 7,329 shares of the medical research company’s stock valued at $459,000 after purchasing an additional 7,209 shares during the period. Russell Investments Group Ltd. raised its position in Natera by 378.0% in the fourth quarter. Russell Investments Group Ltd. now owns 64,679 shares of the medical research company’s stock valued at $4,051,000 after purchasing an additional 51,147 shares during the period. Victory Capital Management Inc. raised its position in Natera by 13.9% in the fourth quarter. Victory Capital Management Inc. now owns 26,109 shares of the medical research company’s stock valued at $1,635,000 after purchasing an additional 3,178 shares during the period. Natixis Advisors L.P. raised its position in Natera by 29.9% in the fourth quarter. Natixis Advisors L.P. now owns 19,553 shares of the medical research company’s stock valued at $1,224,000 after purchasing an additional 4,497 shares during the period. Finally, M&T Bank Corp raised its position in Natera by 11.6% in the fourth quarter. M&T Bank Corp now owns 5,424 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 565 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total value of $185,946.90. Following the completion of the transaction, the chief financial officer now directly owns 71,955 shares in the company, valued at $7,170,315.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90. Following the completion of the transaction, the chief financial officer now directly owns 71,955 shares in the company, valued at $7,170,315.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the transaction, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The disclosure for this sale can be found here. Insiders sold a total of 92,388 shares of company stock worth $10,205,064 over the last ninety days. Company insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of several research reports. Canaccord Genuity Group raised their price objective on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and set a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Robert W. Baird lifted their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Morgan Stanley lifted their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $120.07.

Natera Stock Down 3.9 %

NASDAQ:NTRA traded down $4.60 during mid-day trading on Friday, reaching $112.90. The stock had a trading volume of 946,364 shares, compared to its average volume of 1,379,358. The company has a market capitalization of $13.86 billion, a price-to-earnings ratio of -36.19 and a beta of 1.48. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $124.83. The stock’s 50 day simple moving average is $111.58 and its two-hundred day simple moving average is $102.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. Equities analysts anticipate that Natera, Inc. will post -2.03 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.